Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CodaVax-H1N1 in Healthy Adults
NCT05223179Phase 1Completed
- Sponsor
- Codagenix
- Start
- Apr 2022
- Primary completion
- Feb 2024
- Modality
- Live Attenuated Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of CodaVax-H1N1 in influenza (3 arms), sponsored by Codagenix. Primary endpoints: Percentage of Participants with Reactogenicity Events, Percentage of Participants with Adverse Events and 1 more. Started Apr 2022; status: completed.
02
Drugs
CodaVax-H1N1
03
Conditions
influenza
Beyond the preview
Go deeper on NCT05223179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05223179.